Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

A Synergistic Combination of Oleanolic Acid and Apatinib to Enhance Antitumor Effect on Liver Cancer Cells and Protect against Hepatic Injury

Author(s): Juan Ren, Jun Yan, Faisal Raza*, Hajra Zafar, Haopeng Wan, Xue Chen, Qingrong Cui, Haiyang Li and Xiangqi Wang*

Volume 19, Issue 2, 2024

Published on: 05 May, 2023

Page: [199 - 208] Pages: 10

DOI: 10.2174/1574892818666230417093208

Price: $65

Abstract

Background: As a pentacyclic triterpenoid, OA (oleanolic acid) has exhibited antiinflammatory, immunomodulatory and antitumor effects. VEGFR-2 (vascular endothelial cells receptor-2) tyrosine kinase activity could be inhibited by apatinib, a small-molecule antiangiogenic agent.

Objective: Thus, this study sought to investigate the mechanism underlying the synergistic antitumor activity of combined OA and apatinib patent.

Methods: Through CCK8 (Cell counting kit 8 assay), flow cytometric and western blotting techniques, we conducted in vitro studies on apatinib and OA effects on cell proliferation and apoptosis in H22 cell line. H22 tumor-burdened mice model was established in vivo, while the related signaling pathways were studied via pathological examination, western blotting and qPCR (quantitative polymerase chain reaction).

Results: Growth of H22 cells in vitro and in vivo could be inhibited effectively by apatinib and OA. Thus, OA repaired liver function and inhibited oxidative stress induced by apatinib.

Conclusion: OA can treat apatinib induced liver injury in H22 Tumor-burdened mice by enhancing the suppresssive effect of apatinib on the growth of tumor.

« Previous Next »
[1]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Fernandez Varo G, Franco Puntes V, Jimenez Povedano W. New single-crystal cerium oxide nanoparticle used for treating hepatocellular carcinoma. Patent WO2017174437-A1, 2017.
[3]
Huang T, Zhang Z, Kong X, et al. Use of glycogen synthase kinase-3 beta inhibitor for preparing medicine for improving curative effect of anti-hepatocellular carcinoma and for improving the survival rate of hepatocellular carcinoma patients, and for preparing medicine for enhancing immunotherapy efficacy of hepatocellular carcinoma. Patent CN114796482-A, 2016.
[4]
Wilhelmi M. Systemic therapies in elderly patients with advanced hepatocellular carcinoma: Do not forget metronomic capecitabine. Eur J Surg Oncol 2021; 47(8): 2208-8.
[http://dx.doi.org/10.1016/j.ejso.2021.04.014] [PMID: 33906788]
[5]
Zhang H. Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther 2015; 9: 6075-81.
[http://dx.doi.org/10.2147/DDDT.S97235] [PMID: 26622168]
[6]
Ding J, Chen X, Dai X, Zhong D. Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography–tandem mass spectrometry and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 895-896: 108-15.
[http://dx.doi.org/10.1016/j.jchromb.2012.03.027] [PMID: 22503745]
[7]
Xue J, Astère M, Zhong M, Lin H, Shen J, Zhu Y. Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: A meta-analysis. OncoTargets Ther 2018; 11: 6119-28.
[http://dx.doi.org/10.2147/OTT.S172717] [PMID: 30288047]
[8]
Xi-Hao. Zhang MQ, Cao XX, Li T. Apatinib as an alternative therapy for advanced hepatocellular carcinoma. World J Hepatol 2020; 12(10): 78-86.
[9]
Liu QY, Wang X. A case of severe acute liver injury induced by apatinib. Mil Med Sci 2019; 26(02): 246-8.
[10]
Hao BB, Pan XX, Fan Y, et al. Oleanolic acid attenuates liver ischemia reperfusion injury by HO-1/Sesn2 signaling pathway. Hepatobiliary Pancreat Dis Int 2016; 15(5): 519-24.
[http://dx.doi.org/10.1016/S1499-3872(16)60115-7] [PMID: 27733322]
[11]
Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23(16): 2838-49.
[http://dx.doi.org/10.1038/sj.onc.1207556] [PMID: 15077147]
[12]
Zhu YY, Huang HY, Wu YL. Anticancer and apoptotic activities of oleanolic acid are mediated through cell cycle arrest and disruption of mitochondrial membrane potential in HepG2 human hepatocellular carcinoma cells. Mol Med Rep 2015; 12(4): 5012-8.
[http://dx.doi.org/10.3892/mmr.2015.4033] [PMID: 26151733]
[13]
Shanmugam MK, Dai X, Kumar AP, Tan BKH, Sethi G, Bishayee A. Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: Preclinical and clinical evidence. Cancer Lett 2014; 346(2): 206-16.
[http://dx.doi.org/10.1016/j.canlet.2014.01.016] [PMID: 24486850]
[14]
Lin C, Wen X, Sun H. Oleanolic acid derivatives for pharmaceutical use: A patent review. Expert Opin Ther Pat 2016; 26(6): 643-55.
[http://dx.doi.org/10.1080/13543776.2016.1182988] [PMID: 27113324]
[15]
Duan L, Yang Z, Jiang X, Zhang J, Guo X. Oleanolic acid inhibits cell proliferation migration and invasion and induces SW579 thyroid cancer cell line apoptosis by targeting forkhead transcription factor A. Anticancer Drugs 2019; 30(8): 812-20.
[http://dx.doi.org/10.1097/CAD.0000000000000777] [PMID: 30882397]
[16]
Chu P, Li H, Luo R, et al. Oleanolic acid derivative SZC014 inhibit cell proliferation and induce apoptosis of human breast cancer cells in a ROS-dependent way. Neoplasma 2017; 64(5): 681-92.
[http://dx.doi.org/10.4149/neo_2017_505] [PMID: 28592114]
[17]
Scott AJ, Messersmith WA, Jimeno A. Apatinib: A promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today 2015; 51(4): 223-9.
[http://dx.doi.org/10.1358/dot.2015.51.4.2320599] [PMID: 26020064]
[18]
Li L, Kong F, Zhang L, et al. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: Data from an open-label, single-arm, exploratory study. Invest New Drugs 2020; 38(6): 1847-53.
[http://dx.doi.org/10.1007/s10637-020-00925-2] [PMID: 32363427]
[19]
Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 2011; 102(7): 1374-80.
[http://dx.doi.org/10.1111/j.1349-7006.2011.01939.x] [PMID: 21443688]
[20]
Golob-Schwarzl N, Krassnig S, Toeglhofer AM, et al. New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors. Eur J Cancer 2017; 83(05): 56-70.
[http://dx.doi.org/10.1016/j.ejca.2017.06.003] [PMID: 28715695]
[21]
Zhang LP, Yan Z, Liu GJ, Yang DG, Zhou LH. Glabridin attenuates lipopolysaccharide-induced acute lung injury by inhibiting p38MAPK/ERK signaling pathway. Chinese Pharmacol Bull 2016; 32(12): 1311-6.
[22]
Mu DW, Guo HQ, Zhou GB, Li JY, Su B. Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling. Int J Clin Exp Pathol 2015; 8(11): 13864-70.
[PMID: 26823699]
[23]
Shi Y, Song Q, Hu D, Zhuang X, Yu S, Teng D. Oleanolic acid induced autophagic cell death in hepatocellular carcinoma cells via PI3K/Akt/mTOR and ROS-dependent pathway. Korean J Physiol Pharmacol 2016; 20(3): 237-43.
[http://dx.doi.org/10.4196/kjpp.2016.20.3.237] [PMID: 27162477]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy